Anti-HLA-A2-WT1/Anti-CD3 T-cell Engaging Bispecific Antibody RO7283420

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell receptor (TCR)-like T-cell engaging bispecific antibody (T-BsAb) targeting both the RMFPNAPYL nonapeptide (RMF peptide), which is derived from the intracellular Wilms tumor 1 (WT1; WT-1) and presented on human leukocyte antigen A2 (HLA-A2), and the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific antibody RO7283420 simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and the HLA-A2 WT1 complex found on WT1-expressing tumor cells. This activates and redirects CTLs to WT1-expressing tumor cells, which results in the CTL-mediated cell death of WT1-expressing tumor cells. WT1, an intracellular oncoprotein and transcription factor, is overexpressed in a variety of tumor cell types.

**Synonyms:** - HLA-A2-WT1 x CD3 RG6007 - HLA-A2-WT1xCD3 T-cell Engaging Bispecific Antibody RO7283420 - RG 6007 - RG-06007 - RG6007 - RMF-peptide-MHC-specific T-cell Bispecific Antibody RG6007 - RO 7283420 - RO-7283420 - RO7283420